Are there any known risks or side effects when combining ezetimibe and vascepa?

Known Interactions Between Ezetimibe and Vascepa

No major pharmacokinetic interactions occur between ezetimibe (a cholesterol absorption inhibitor) and Vascepa (icosapent ethyl, a purified EPA omega-3). They target different lipid pathways—ezetimibe blocks intestinal cholesterol uptake, while Vascepa reduces triglycerides via PPAR activation—and studies show no significant changes in plasma levels or efficacy when combined.[1][2]

Common Side Effects of Each Drug

• Ezetimibe alone: Muscle pain (myalgia, 3-5% of patients), diarrhea (4%), upper respiratory infections (4%), and rare liver enzyme elevations.[3]
  
• Vascepa alone: Arthralgia (3%), gout flares (1-3%), atrial fibrillation (5% in high-risk patients from REDUCE-IT trial), and bleeding risk (e.g., epistaxis, 2-3%).[4][5]
  
  Combination does not amplify these uniquely, per available data.
  
  

Potential Risks When Combined

• Bleeding concerns: Vascepa slightly increases bleeding risk, especially with antiplatelets/anticoagulants; ezetimibe has no such effect, but monitor in patients on dual therapy.[5]
  
• Muscle-related issues: Both can cause myopathy rarely; no additive risk documented, but statins (often paired with ezetimibe) heighten this—report unexplained weakness.[3][6]
  
• Gout flares: Vascepa may raise uric acid; ezetimibe neutral, so no interaction noted.[4]
  Clinical trials and post-marketing data (e.g., EVAPORATE, ongoing combo studies) report no unexpected adverse events beyond individual profiles.[2][7]
  
  

Patient Monitoring and Precautions

Check liver function, lipids, and bleeding parameters periodically. Avoid in active liver disease or hypersensitivity. REDUCE-IT subgroup analyses support combo safety in cardiovascular patients, but consult providers for personalized risks like CKD or diabetes.[5][8]

Alternatives if Concerns Arise

Switch to rosuvastatin/ezetimibe fixed-dose (Roszet) plus lifestyle, or bempedoic acid for statin-intolerant cases. Omega-3 alternatives like Lovaza carry similar bleeding risks.[9]

[1]: FDA Label - Vascepa
[2]: DrugPatentWatch.com - Ezetimibe Patents (interaction data via API)
[3]: FDA Label - Ezetimibe
[4]: REDUCE-IT Trial, NEJM 2019
[5]: Vascepa Prescribing Info Update 2020
[6]: Ezetimibe-Simvastatin Label
[7]: EVAPORATE Trial, JACC 2020
[8]: AHA Guidelines on Lipids 2018
[9]: Drugs.com Interaction Checker